06:34pm Saturday 22 February 2020

Childhood Cancer Survivors Face Increased Risk of Metabolic Syndrome and Premature Cardiovascular Disease

These factors have been linked to the effects of chemotherapy and radiation therapy and are key contributors to the metabolic syndrome, which increases a patient’s risk for cardiovascular disease, as described in an article in Journal of Adolescent and Young Adult Oncology (JAYAO), a multidisciplinary peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free to download on the JAYAO website until February 25, 2016.

The article “Metabolic Health in Childhood Cancer Survivors: A Longitudinal Study in a Long-Term Follow-Up Clinic” reports that hypertension was common in the study population of childhood cancer survivors who had been cancer-free for at least 5 years, affecting nearly 1 in 5 individuals and significantly more males and young adults 18 years of age or older. Other significant results included the finding that previous irradiation of the head is a risk factor for overweight/obesity.

Harriet Gunn, MBBS, Melissa Gabriel, MBBS, Ann Maguire, MBBS, PhD, Katharine Steinbeck, MBBS, PhD, The Children’s Hospital at Westmead and The University of Sydney (New South Wales, Australia), and Hanna Emilsson, Linkoping University (Sweden), emphasize the need to improve early identification and monitoring of metabolic health risks in this pediatric population, develop a clear definition of pediatric metabolic syndrome, and implement targeted interventions to minimize metabolic complications.

“Metabolic syndrome is becoming ever more relevant to young cancer survivors, and the authors of this article describe and frame the problem in a way that will help the AYA academic field find solutions, as defined and outlined in the paper,” says Editor-in-Chief Leonard S. Sender, MD, University of California, Irvine and CHOC Children’s Hospital, Orange, CA.

Click here to share this press release with your colleagues.

About the Journal
Journal of Adolescent and Young Adult Oncology (JAYAO) is a quarterly peer-reviewed journal dedicated to the promotion of interdisciplinary research, education, communication, and collaboration between health professionals in AYA oncology. JAYAO provides a forum for AYA cancer research and practice advances for all professional participants and researchers in care for AYA-aged cancer patients and survivors. The Journal’s multidisciplinary editorial board and readership includes but is not limited to: pediatric, medical, and surgical oncologists of all types and specialties; oncology nurses and advanced practice staff; psychosocial and supportive care providers including psychiatrists, psychologists, and social workers; translational cancer researchers; and academic- and community-based pediatric and adult cancer institutions. Complete tables of content and a sample issue may be viewed on the Journal of Adolescent and Young Adult Oncology (JAYAO) website.

About the Society
The Society for Adolescent and Young Adult Oncology (SAYAO) is an international professional organization dedicated to improving adolescent and young adult cancer care through the promotion of interdisciplinary research, education, communication, and collaboration among health professionals. Patients and survivors aged 15-39 are a distinct patient population within oncology, and SAYAO focuses on the unique biological, clinical, psychosocial, and survivorship issues of this age group.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Journal of Palliative Medicine and Cancer Biotherapy and Radiopharmaceuticals. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.

Share on:

MORE FROM Heart disease

Health news